ARTICLE | Clinical News
Histalean: Phase Ib data
June 22, 2009 7:00 AM UTC
Top-line data from the double-blind, placebo-controlled Phase Ib BET-209 trial in 48 healthy pre-menopausal women showed that 144 mg/day Histalean was safe with no serious adverse events. In the inten...